전이성 대장암 환자에서 Oxaliplatin 반응군과 비반응군과의 비교
Comparison between Responder and Non- responder of Oxaliplatin Chemotherapy for Metastatic Colorectal Cancer
조민미, 배옥석, 백성규, 이태순, 박성대,
소속 상세정보
조민미 ( Cho Min-Mi )
계명대학교 의과대학 외과학교실
배옥석 ( Bae Ok-Suk )
계명대학교 의과대학 외과학교실
백성규 ( Baek Seong-Kyu )
계명대학교 의과대학 외과학교실
이태순 ( Lee Tae-Soon )
계명대학교 의과대학 효성병원
박성대 ( Park Sung-Dae )
계명대학교 의과대학 외과학교실
KMID : 0356720060220060411
Abstract
Purpose: The purpose of this study was to evaluate the clinicopathological significance of responders with metastatic colorectal cancer treated with oxaliplatin chemotherapy.
Methods: A total of 52 patients with unresectable metastatic colorectal cancer were enrolled for treatment between March 2000 and August 2005. Patients received first line chemotherapy consisted of oxaliplatin 85 mg/m2 or 130 mg/m2 as a 2-hour infusion on day 1, concurrently with leucovorin (LV) 20 mg/m2 as a bolus infusion on day 1∼5, followed by continuous infusion of 5-fluorouracil (5-FU) 425 mg/m2 on day 1∼5. This treatment was repeated in 2 or 3 week intervals. All responses were assessed after 4 cycles of therapy by independent radiologic experts and categorized into two groups: responder (major reduction of tumor) and non-responder group (no change or progression of the tumor.
Results: The response rate was 51.9 percent (27/52 patients). There were no significant differences in clinicopathologic parameters between two groups. The decrease of CEA value after chemotherapy was significantly more frequent in the responder group than in the non-responder group.
Conclusion: We could not find any clinical differences between the two groups, but these results suggest that oxaliplatin chemotherapy has a beneficial effect on tumor shrinkage and serum CEA value can be an indicator for tumor response of oxaliplatin in advanced colorectal cancer. J Korean Soc Coloproctol 2006;22:411-417
키워드
옥살리플라틴;결장직장암
Oxaliplatin;Colorectal neoplasm
원문 및 링크아웃 정보
등재저널 정보